Description: Invitae Corporation processes DNA-containing samples, analyzes information about patient-specific genetic variation, and generates test reports for physicians and their patients using an integrated portfolio of laboratory processes, software tools, and informatics capabilities. The company's product is an assay of 216 genes associated with hereditary cancer, neurological disorders, cardiovascular disorders, and other hereditary conditions comprising 85 various genetic disorders and 17 targeted panels. It also solutions that enable sharing of genetic information consisting of Invitae Family History Tool, a Web or iPad application, which provides family history; and Clinvitae, a Web property that allows physicians or patients to look up individual genes and variants in order to find out additional genetic information. It operates in the United States, Israel, and internationally. The company was formerly known as Locus Development, Inc. and changed its name to Invitae Corporation in 2012. Invitae Corporation was founded in 2010 and is headquartered in San Francisco, California.
Home Page: www.invitae.com
NVTA Technical Analysis
1400 16th Street
San Francisco,
CA
94103
United States
Phone:
415 374 7782
Officers
| Name | Title |
|---|---|
| Mr. Kenneth D. Knight | Pres, CEO & Director |
| Ms. Yafei Wen | Chief Financial Officer |
| Mr. Thomas R. Brida | Gen. Counsel, Chief Compliance Officer & Sec. |
| Dr. Robert L. Nussbaum M.D. | Chief Medical Officer |
| Ms. Shelly D. Guyer | Chief Sustainability Officer |
| Mr. Robert F. Werner | Chief Accounting Officer & Principal Accounting Officer |
| Ms. Hoki Luk | Head of Investor Relations and Capital Markets |
| Mr. Lee Bendekgey J.D. | Chief Policy Officer |
| Glenn Medalle | Head of Talent |
| Ms. Desarie French | Chief Talent Officer |
Exchange: NYSE
Country: US : United States of America
Currency: US Dollar ($)
| GIC Sector: | Health Care |
|---|---|
| GIC Group: | Pharmaceuticals, Biotechnology & Life Sciences |
| GIC Industry: | Biotechnology |
| GIC Sub-Industry: | Biotechnology |
| Forward PE: | 0 |
|---|---|
| Trailing PE: | 0 |
| Price-to-Book MRQ: | 3.3178 |
| Price-to-Sales TTM: | 0.9413 |
| IPO Date: | 2015-02-12 |
| Fiscal Year End: | December |
| Full Time Employees: | 3000 |